By Yafo Life Sciences
December 26th, 2021 (Shanghai) — We are glad to announce that Hoonmo Lee, the CEO of REDNVIA CO., LTD., has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About REDNVIA CO., LTD.
REDNVIA is a clinical-stage pharmaceutical company focusing on transformative therapies for cardiovascular diseases, especially developing the RNV-1001 program (DA-1229/Evogliptin) as a treatment for CAVD (Calcific Aortic Valve Disease) that doesn’t have any approved therapy so far.
About the speaker
Hoonmo Lee worked as a manager at Eli Lilly, CHA health systems, and as a BD Head of Korea Drug Development Fund before found REDNVIA, that who has diverse experience in the bio-healthcare sector.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: